Ositab is one of the recommended brands in the oncology division that manage the EGFR mutated NSCLC (Non-small cell lung cancer) in patients who have already progressed on or after taking EGFR TKI therapy. It comes in two dose forms and is prescribed accordingly based on the clinical condition of the patient. Click on the appropriate link below to view more details like uses, composition, and description of the products.
"DYRONIB" belongs to Tyrosine Kinase Inhibitor therapy of Oncology Division. It is available in Tablet dosage form and available in three strengths : Dasatinib 20Mg Tablet, Dasatinib 50Mg Tablet and Dasatinib 70Mg Tablet.
To order or to know more details about Menthopas, reach us by filling the form. We will get back you within 1-2 business days.
Plot Nos. M-22 & M-25; Motanga Industrial Park, S/Jongkhar, Bhutan
Plot Nos. M-22 & M-25; Motanga Industrial Park, S/Jongkhar, Bhutan
